Psivant Therapeutics

Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design that is tightly coupled to chemistry and biology research and development. Our QUAISAR platform is purpose-built to develop novel small molecule therapeutics to address biologically and genetically validated, but previously intractable, protein targets.

Research Boston, United States ~27 employees

Work at Psivant Therapeutics in HR or recruiting? Claim this page

Employees
27
0% in the 3 months to Feb 2025
12-month attrition
28.1%
Tech: 18.3%
H1B filings, FY2026
3
Sponsors visas
Open jobs
1
Last 30 days

Headcount trend

Psivant Therapeutics went from 24 employees in Mar 2023 to 27 in Feb 2025. Sep 2024 to Feb 2025: 5 people joined, 1 left.

Headcount data through Feb 2025

Org structure

Headcount by department

Other19
Engineering6
Operations2

H-1B sponsorship

H-1B Sponsorship Limited
H-1B Filings by Department
Engineering3

Peer reviews

Worked with someone at Psivant Therapeutics?

Anonymous peer reviews on OffTheRecord

Read or write a review

Hiring now

Similar companies

Psivant Therapeutics FAQ

How many employees does Psivant Therapeutics have?

Psivant Therapeutics has about 27 employees, unchanged over the 3 months to Feb 2025.

Does Psivant Therapeutics sponsor H1B visas?

Yes. Psivant Therapeutics filed 3 H1B (LCA) applications in FY2026, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.